

**Research Ethics Service** 

# South Central - Hampshire B Research Ethics Committee

# **Annual Report**

# 01 April 2015 - 31 March 2016



## Part 1 – Committee Membership and Training

Name of REC:	South Central - Hampshire B Research Ethics Committee
Type of REC:	RECs recognised to review CTIMPS in patients - type iii
Type of Flag:	Establishing Research Tissue Banks IRB Registered
Chair:	Professor Ron King
Vice-Chair:	Dr Giles Tan (01/04/2013 - 14/09/2015) Dr Andrew Scott (14/09/2015 – present)
Alternate Vice-Chair:	Dr Andrew Scott (17/03/2015 – 14/09/2015) Mr Brian Birch (23/09/2015 – present)
REC Manager:	Miss Libby Watson (upto 01/05/2015) Mrs Maeve Ip Groot Bluemink (01/05/2015 – 01/10/2015) Mrs Siobhan Bawn (01/10/2015 – present)
REC Assistant:	Natasha Bridgeman (upto 01/05/2015) Sadie McKeown-Keegan (01/05/2015 – 01/10/2015)
Committee Address:	Level 3 Block B Whitefriars Lewins Mead Bristol BS1 2NT
Telephone:	0207 104 8052
Email:	nrescommittee.southcentral-hampshireb@nhs.net

#### Chair's overview of the past year:

This year the main Committee has dealt with 47 applications, all within the 60 day time limit but it is slightly disappointing to note that 4 exceeded the key performance target of 40 days. For various reasons, including problems encountered in 22 cases at the validation stage, the various Proportionate Review Sub-Committees dealt with only 14 validated applications, but completed them all within the 14 day target. Ordinary Sub-Committees dealt with no less than 119 Substantial Amendments with just 7 extending to 28 days but none as long as 35 days. Whilst the work of the Committee can be assessed only in part in such numerical terms, these figures indicate a continuing commitment to undertaking its review work for the HRA both diligently and efficiently. All contributing members, as well as those backing them up in the South Central office, are to be congratulated on this.

There have been several changes at officer level during the year. We were sorry to lose Giles Tan whose service as Vice-Chair had been invaluable. He was always a thoughtful contributor to discussions within the Committee and was particularly good at questioning researchers. As Chair, I am greatly indebted to him for his practical support and encouragement over many years. Having deputised for Giles for some time, Andrew Scott formally took over as Vice-Chair, with Brian Birch being appointed later in the year as Alternate Vice-Chair. They have both played a significant role not only in the deliberations of the main Committee, but also in chairing various Sub-Committees.

Changes have also taken place at REC Manager level. Last year we welcomed Maeve Groot Bluemink to this post, but her appointment turned out to be temporary while a major re-shuffle took place at the Bristol office. Maeve was succeeded by Siobhan Bawn, to whom much of the credit must go for the smooth functioning of the Committee this year. In the absence of any permanent Assistant, Siobhan was supported in her part-time role by a number of assistants - and also at times of need by Libby Watson.

As far as Committee membership is concerned, we lost Megan Barlow-Pay after all too short a time with us, and also Ita Berry who had been a founder member of the merged Committee. She could always be relied upon to uphold the interests of research participants and took on more than her share of work at a time when we were very short of lay members. To relieve the situation Lisa Armstrong has now joined us on a short term basis. Then the membership was further boosted with Ravina Barrett, Diane Ackerley, Alessandro di Nicola and Becci Petch all joining us in quick succession. The strength of the new team was particularly evident in the case of one particular study involving a number of ethical issues, where post-meeting email correspondence was necessary in connection with an external expert review. I believe that that the deliberations both in the meeting itself and subsequently in correspondence, showed both new and old members working extremely effectively together to achieve an appropriate consensus.

Having announced my own departure after 10 years on the Hampshire B Committee and its predecessor Southampton B, I can report I am leaving at a time when the combined membership has rarely, if ever, been stronger. It has been a pleasure and a privilege to serve as a member and Chair, and to have worked with so many volunteers and supporting personnel who are all intent on protecting participants whilst facilitating high quality medical research. I wish the Committee well in all its future endeavours.

#### South Central - Hampshire B Research Ethics Committee Membership

Name	Profession	Expert or	Da	tes
		Lay	Appointed	Left
Dr Diane Ackerley	Retired Doctor	Expert	01/01/2016	
Mrs Lisa Armstrong	Senior Lecturer Social Work	Lay	10/12/2015	
Ms Megan Barlow-Pay	Patient and Public Involvement Officer	Lay Plus	21/04/2015	09/11/2015
Mrs Ravina Barrett	Pharmacist	Expert	25/11/2015	
Mrs Ita Berry	Clinical Psychologist (Retired)	Lay	01/04/2013	25/08/2015
Mr Brian Birch	Consultant Urological Surgeon	Expert	01/04/2013	
Mrs Janet Brember	Pharmacist	Expert	01/04/2013	
Ms Julie Brinton	Speech and Language Therapist	Expert	23/02/2015	
Mr Mark Cassidy	Senior Lecturer in Radiography	Expert	01/04/2013	
Dr Alessandro di Nicola	Lecturer in Philosophy	Lay Plus	01/01/2016	
Ms Susan Edwards	Lead Contract Manager, NHS South West and Central Contract Support Unit	Lay	27/01/2015	
Mrs Angela Iveson	Acute Oncology Clinical Nurse Specialist	Expert	01/04/2013	
Professor Ron King	Mathematician (Retired)	Lay Plus	01/04/2013	
Mr Geoff Lowndes	Chartered Engineer (Retired)	Lay Plus	01/04/2013	
Miss Becci Petch	Clinical Trial Coordinator	Lay	08/02/2016	
Dr Andrew Scott	Course Leader, M.Sc. Clinical Exercise Science	Expert	01/04/2013	
Dr Giles Tan	Consultant Psychiatrist	Expert	01/04/2013	12/11/2015

#### South Central - Hampshire B Research Ethics Committee: Deputy Members

Name	Profession	Status	Meeting date attended

#### South Central - Hampshire B Research Ethics Committee: Co-opted Members

Name	Profession	Status	Meeting date attended
Ms Stephanie Ellis	Former Civil Servant	Lay Plus	26/08/2015, 30/09/2016

### South Central - Hampshire B Research Ethics Committee: Members' Declarations of

Name	Declaration of Interest	Date
Dr Diane Ackerley	None	19/01/2016
Mrs Lisa Armstrong	Currently working on a piece of research in Hampshire with Mencop, Cares Togells, and Princess Royal Trust for carers	25/01/2016
Ms Megan Barlow-Pay	Researcher Advisor for Research Design Service	14/05/2015
Mrs Ravina Barrett	None	30/11/2015
Mr Brian Birch	Has previously acted as a paid advisor (ad hoc) for Astellas and Janssen.either received honoraria to speak at, chair and attend meetings or liased/received educational material from representatives of the following companies: Astellas, Pfizer, Ipsen, Glaxo Smith Kline, Sanofi, Lilly, Bayer, Amgen, Ferring, Takeda, AstraZeneca, Janssen-Cilag, Janssen	01/02/2016
Mrs Janet Brember	None	19/01/2016
Ms Julie Brinton	Part-time consultancy for Advanced Bionics, manufacturers of cochlear implants. Advanced Bionics is a division of Phonak, a learning aid manufacturer. Parent Company is Sonus.	02/04/2015
Mr Mark Cassidy	Year 3 'Developing Project Skills' Unit Leader, BSc Radiography, University of Portsmouth	25/01/2016
Dr Alessandro Di Nicola	None	12/01/2016
Ms Susan Edwards	None	29/03/2016
Mrs Angela Iveson	Employed as Research Nurse by Salisbury NHS Foundation Trust	31/03/2016
Professor Ron King	Share holds in pharmaceutical companies though managed by a 3rd party.	29/03/2016
Mr Geoff Lowndes	None	28/10/2015
Miss Becci Petch	None	10/02/2016
Dr Andrew Scott	None	12/01/2016
Dr Alessandro Di Nicola	None	12/01/2016

#### Meetings for Full Ethical Review 01 April 2015 - 31 March 2016:

Month	Date	Number of Members Present at Meeting
April	29/04/2015	9
Мау	27/05/2015	9
July	29/07/2015	11
August	26/08/2015	9
September	30/09/2015	8
October	28/10/2015	8
November	25/11/2015	8
January	27/01/2016	13
February	24/02/2016	10

9 full committee meetings were held during the reporting period.

### Proportionate Review Sub-Committee Meetings held during 01 April 2015 - 31 March 2016:

Month	Date	Number of Members Present at Meeting
July	29/07/2015	3
September	30/09/2015	3
November	25/11/2015	3
December	09/12/2015	7
January	27/01/2016	3
February	24/02/2016	3
March	30/03/2016	3

8 proportionate review sub-committee meetings were held during the reporting period.

#### Sub-Committee Meetings held during 01 April 2015 - 31 March 2016:

Month	Date	Number of Members Present at Meeting
April	01/04/2015	2
April	15/04/2015	2
April	29/04/2015	3
May	06/05/2015	2
May	20/05/2015	2
June	03/06/2015	2
June	17/06/2015	2
June	30/06/2015	2
July	06/07/2015	2
July	21/07/2015	2
August	05/08/2015	2
August	19/08/2015	2
September	10/09/2015	2
September	16/09/2015	2
October	05/10/2015	2

October	07/10/2015	2
October	12/10/2015	2
October	21/10/2015	2
November	04/11/2015	2
November	18/11/2015	2
November	20/11/2015	2
November	27/11/2015	2
December	02/12/2015	2
December	04/12/2015	2
December	11/12/2015	2
December	16/12/2015	2
December	30/12/2015	2
January	20/01/2016	2
February	03/02/2016	2
February	05/02/2016	13
February	12/02/2016	3
February	17/02/2016	2
March	02/03/2016	2
March	16/03/2016	2

38 sub-committee meetings were held during the reporting period.

#### Attendance of Members at full committee meetings:01 April 2015 - 31 March 2016

Name	Number of Meetings Attended
Dr Diane Ackerley	2
Mrs Lisa Armstrong	2
Ms Megan Barlow-Pay	3
Mrs Ravina Barrett	3
Mrs Ita Berry	3
Mr Brian Birch	7
Mrs Janet Brember	8
Ms Julie Brinton	8
Mr Mark Cassidy	6
Dr Alessandro di Nicola	1
Ms Susan Edwards	8
Mrs Angela Iveson	7
Professor Ron King	9
Mr Geoff Lowndes	8
Miss Becci Petch	1
Dr Andrew Scott	6
Dr Giles Tan	1

# Attendance of Members at proportionate review sub-committee meetings: 01 April 2015 - 31 March 2016

Name	Number of Meetings Attended
Mrs Ita Berry	1
Mr Brian Birch	3
Mrs Janet Brember	3
Ms Julie Brinton	2
Mr Mark Cassidy	2
Ms Susan Edwards	3
Mrs Angela Iveson	2
Professor Ron King	6
Mr Geoff Lowndes	1
Dr Andrew Scott	2

#### Attendance of Members at sub-committee meetings: 01 April 2015 - 31 March 2016

Name	Number of Meetings Attended
Dr Diane Ackerley	1
Mrs Lisa Armstrong	1
Dr Ronja Bahadori	1

Mrs Ravina Barrett	1
Mrs Ita Berry	3
Mr Brian Birch	7
Mrs Janet Brember	6
Ms Julie Brinton	9
Mr Mark Cassidy	9
Dr Alessandro di Nicola	1
Ms Susan Edwards	3
Mrs Angela Iveson	5
Professor Ron King	20
Mr Geoff Lowndes	3
Dr Andrew Scott	17

## Training 01 April 2015 - 31 March 2016

Name of Member	Date	Event(s) attended
Dr Diane Ackerley	22/02/2016	Equality and Diversity Training
Dr Diane Ackerley	10/03/2016	Member Induction Training
Mrs Lisa Armstrong	08/12/2015	Hampshire A Training Day
Ms Megan Barlow-Pay	22/07/2015	Training - Research Involving
<b>5</b>		the Disadvantaged and
		Vulnerable: a Workshop for
		Researchers and Reviewers
Mrs Ravina Barrett	13/10/2015	Unconscious Bias ENEI
Mrs Ravina Barrett	13/10/2015	Diversity in the Workplace
Mrs Ravina Barrett	31/03/2016	Self-Directed Learning
Mr Brian Birch	26/10/2015	Equality and Diversity Training
Mr Brian Birch	14/11/2015	Training for New REC Chairs
Mr Brian Birch	19/11/2015	Personal Data in Research - A
		Workshop
Mr Brian Birch	03/12/2015	HRA Workshop: Pragmatic or
		Point of Care trials
Mr Brian Birch	08/12/2015	Local Training Day - Hampshire
		A
Mr Brian Birch	14/01/2016	New Chair's Training
Mrs Janet Brember	08/04/2015	Ethics & GCP Forum ICR
Mrs Janet Brember	08/12/2015	Local Training Day - Hampshire
		A
Ms Julie Brinton	29/04/2015	Equality and Diversity Training
Ms Julie Brinton	17/06/2015	Member Induction Training
Ms Julie Brinton	27/11/2015	CTIMP Training Day
Mr Mark Cassidy	22/07/2015	Qualitative Research and
		Ethical Review
Mr Mark Cassidy	03/12/2015	HRA Workshop: Pragmatic or
		Point of Care trials
Dr Alessandro di Nicola	04/01/2016	Equality and Diversity e-module
Ms Susan Edwards	24/09/2015	Member Induction Training
Professor Ron King	04/09/2015	Joint Oxford Training Day
Professor Ron King	27/11/2015	CTIMP Training
Professor Ron King	03/02/2016	Handling Health-Related
		Findings in Research
Professor Ron King	03/02/2016	Handling Health-Related
		Findings in Research (Joint
		MRC/HRA)
Professor Ron King	03/02/2016	Handling Health-Related
		Findings
Dr Andrew Scott	03/06/2015	NREAP South Central Chairs'
		Meeting
Dr Andrew Scott	08/12/2015	Local Training Day - Hampshire
		A
Dr Andrew Scott	12/01/2016	Equality and Diversity

#### PART 2: REC WORKLOAD AND ACTIVITY DURING THE REPORTING PERIOD

# Table 1: Applications assigned to a full committee meeting held within the reporting period:

Applications for full ethical review – Study Type	Number	%
Clinical Trial of Investigational Medicinal Product	15	31.25
Phase 1	0	0.00
Gene Therapy	0	0.00
Research Tissue Bank (including renewals)	1	2.08
Research Database (including renewals)	0	0.00
Others	32	66.67
Total Applications Reviewed	48	100

#### Table 2: Breakdown of full applications and other activity during reporting period

Number of applications made invalid by the REC Manager	2
Number of applications withdrawn prior to the meeting	0
Number of student applications reviewed	19
Number of paediatric applications reviewed	5
Number of device applications reviewed	1
Number of prisoner applications reviewed	0
Number of applications involving adults unable consent reviewed	0
Number of applications reviewed that are funded by the US DHHS	2
Number of qualitative applications reviewed	6

#### Table 3: Decisions given at meetings held within the reporting period

Decisions taken at meetings following review of applications	Number	%
Favourable Opinion with Standard Conditions	0	0.00
Favourable Opinion with Additional Conditions	6	12.77
Unfavourable Opinion	2	4.26
Provisional Opinion	38	80.85
Provisional Opinion Pending Consultation with Referee	1	2.13
Total	47	100
Number of studies sent back to full committee meeting for final opinion	0	

### Table 4: Summary of current status of applications reviewed during the reporting period

Status of applications at date of generation of report	Number	%
Further Information Favourable Opinion with Standard	22	46.81
Conditions		
Further Information Favourable Opinion with Additional	16	34.04
Conditions		
Further Information Unfavourable Opinion	0	0.00
Favourable Opinion with Standard Conditions	0	0.00
Favourable Opinion with Additional Conditions	6	12.77
Unfavourable Opinion	2	4.26
Provisional Opinion	0	0.00
Provisional Opinion Pending Consultation with Referee	0	0.00
Further Information response not complete	0	0.00
No decision entered on system	0	0.00
Number of studies withdrawn after the meeting	1	2.13
Total	47	100

# *Table 5:* Applications assigned to a proportionate review sub-committee within the reporting period

Total Applications Reviewed	14
rotar rippiloatione riemou	••

#### Table 6: Breakdown of PRS applications and other activity during reporting period:

Number of applications made invalid by the REC Manager	22
Number of studies withdrawn prior to the meeting	1
Number of student applications reviewed	7
Number of paediatric applications reviewed	1
Number of device applications reviewed	0
Number of qualitative applications reviewed	1

# *Table 7:* Decisions given at proportionate review sub-committee meetings held within the reporting period

Decisions taken at proportionate review sub- committee meetings	Number	%
Favourable Opinion with Standard Conditions	2	14.29
Favourable Opinion with Additional Conditions	4	28.57
No Opinion transfer to full committee for review	0	0.00
Provisional Opinion	8	57.14
Unfavourable Opinion	0	0.00
Total	14	100

Table 8: Other Management Information based on the number of completed applications for

Average number of applications reviewed per full meeting	5.22
Number of completed applications for full ethical review	46
Number of completed applications for full ethical review over 60 days	0
Number of completed applications over 60 days as a % of total	0.00%
Number of completed applications for full ethical review over 40 days	4
Number of completed applications over 40 days as a % of total	8.51%
Number of days taken to final decision – average (mean)	33

Number of completed proportionate review applications for ethical review	14
Number of completed proportionate review applications for ethical review over 14 days	0
Number of completed proportionate review applications over 14 days as a % of total	0.00%

Number of SSAs (non-Phase 1) reviewed	8
Number of completed applications for SSA review over 25	0
days	
Number of completed applications for SSA review over 25	0.00%
days as % of all non- Phase 1 SSAs	

Number of SSAs (Phase 1) reviewed	0
Number of completed applications for SSA review over 14	0
days	
Number of completed applications for SSA review over 14	0.00%
days as % of all Phase 1 SSAs	

Number of substantial amendments reviewed	119
Number of completed substantial amendments over 35 days	1
Number of completed substantial amendments over 35 days	0.84%
as a % of total substantial amendments	
Number of completed substantial amendments over 28 days	7
Number of completed substantial amendments over 28 days	5.88%
as a % of total substantial amendments	

Number of modified amendments reviewed	5
Number of completed modified amendments over 14 days	0
Number of completed modified amendments over 14 days as	0.00%
a % of total modified amendments	

Number of minor amendments received	71
Number of substantial amendments received for information	1
Number of substantial amendments received for new	17
sites/PIs	
Number of annual progress reports received	239

Number of safety reports received	80
Number of Serious Adverse Events received	6
Number of final reports received	81

REC Reference	Title	Number of Days on Clock
15/SC/0173	Understanding the Narratives of Alcohol Related Liver Disease	32
15/SC/0256	Inhaled Interferon Beta-1a vs placebo in asthma patients	24
15/SC/0415	Quality of life of patients with cancer of known and unknown primary	35
15/SC/0429	Prospective study of understudied drugs in children	28
15/SC/0430	JVDB: Second Line Gastric/Gastroesophageal Cancer	35
15/SC/0442	The ANODE Trial	35
15/SC/0461	Does Gut Permeability Alter after Gastric Bypass in Type 2 Diabetes?	40
15/SC/0478	The DON'T ITCH Trial. Version 1.0	28
15/SC/0565	Targeted Radiotherapy for AL-Amyloidosis – 'TRALA'	32
15/SC/0569	Royal Brompton & Harefield NHS Foundation Trust Tissue Bank V2.0	38
15/SC/0573	Prevalence of depression and anxiety post-myocardial infarction	25
15/SC/0592	LittleEARS study	31
15/SC/0619	Liver function assessment by breath analysis	23
15/SC/0627	comparison of fish oil with modified seed oil	33
15/SC/0633	Delcath PHP-HCC-202 study, v6	25
15/SC/0720	The Six-Minute Walk Test in Pregnant Women – a Reference Range Study	29
16/SC/0036	Phase 1b Study of Necitumumab with Pembrolizumab in Advanced NSCLC	35
16/SC/0040	Exploring mindfulness for older adults with dementia and their carers	34
16/SC/0083	Breathing patterns before and after breathing retraining for asthma	41
16/SC/0103	TrueColours Ulcerative Colitis Version 1.0	30
16/SC/0106	POINT, v1.1 06Aug15	32

REC Reference	Title	Number of Days on Clock
15/SC/0253	TBEYE	32
15/SC/0265	The effect of ulcerative colitis on personal relationships	35
15/SC/0312	Particulate production during debond of orthodontic fixed appliances	36
15/SC/0436	Prevalence and Correlates of Debt in Bipolar Disorder and Depression.	35
15/SC/0439	The relationship between clients with BPD and their Care Coordinators	35
15/SC/0451	True NTH UK – Post Surgical Follow up	38
15/SC/0482	Psychological symptoms in Carcinoid Syndrome. v1.0	36

15/SC/0486	Woman's wellbeing, Aquanatal exercise and Peer Support (Version 2)	29
15/SC/0506	Mybirthplace ; useful for helping inform womens decision making ? 3.0	51
15/SC/0623	Emergency and Urgent Admissions for Psychiatric Conditions	32
15/SC/0640	CALYPSO	35
15/SC/0702	Growth in gastroschisis	35
15/SC/0725	Gait Cycle Analysis after Physica KR Total Knee Replacement	50
16/SC/0041	Integrating palliative care into management of advanced liver disease	35
16/SC/0082	HCN channel function in human tissue	33

<b>Further Informatie</b>	on Unfavourable Opinion	
<b>REC Reference</b>	Title	Number of Days on Clock

Favourable Opinion with Standard Conditions		
<b>REC Reference</b>	Title	Number of Days on Clock
400/02/W	Alcohol Consumpiton Studies in Hepatology Patients	26

Favourable Opinion with Additional Conditions		
<b>REC Reference</b>	Title	Number of Days on Clock
15/SC/0289	AMG 319 in HPV negative HNSCC	26
15/SC/0291	MO29518 - A phase II Study of MPDL3280A in Advanced Solid Tumours	26
15/SC/0315	BP29360 - RO5479599 in advanced or metastatic squamous NSCLC	26
15/SC/0567	Cystic fibrosis diagnosis in adulthood: Patients' views Version 1	24
15/SC/0630	Endorings assisted colonoscopy for polyp detection (version 1.0)	20
15/SC/0784	Exercise training in oesophageal/gastric cancer patient	54

Unfavourable Opinion		
<b>REC Reference</b>	Title	Number of Days on Clock
15/SC/0189	Woman's wellbeing, Aquanatal exercise and Peer Support	23
15/SC/0297	Outcomes of obstetric anal sphincter injuries	26

### **Provisional Opinion**

South Central - Hampshire B Research Ethics Committee Research Ethics Committee Annual Report

Provisional Opinion Pending Consultation with Referee		
<b>REC Reference</b>	Title	Number of Days on Clock

Further information response not complete		
<b>REC Reference</b>	Title	Number of Days on Clock
16/SC/0030	South Coast Observational Study	n/a
16/SC/0038	Anxiety and sexual function	n/a

Withdrawn after the meeting		
<b>REC Reference</b>	Title	Number of Days on Clock
16/SC/0026	HIMM-AD - HICSD in Mild to Moderate Alzheimer's Disease	34

## Table 9.2: Breakdown of current status of all PRS applications reviewed within the reporting period

Further Information Favourable Opinion with Standard Conditions		
<b>REC Reference</b>	Title	Number of Days on Clock
15/SC/0496	Test-retest operator typical error for tHb-mass measurement.	10
15/SC/0614	EBC biomarkers and cough in IPF	12
15/SC/0760	Outcomes of tension-free vaginal tape for stress incontinence	11
16/SC/0127	COMBAT-ID 1	13

Further Information Favourable Opinion with Additional Conditions		
<b>REC Reference</b>	Title	Number of Days on Clock
15/SC/0756	The VANTAGE Study	11
15/SC/0757	Exploring perceptions of blood transfusion in haematology	10
15/SC/0762	Babies' Early Language Development (Version 01)	11
16/SC/0057	Assessment of the accuracy of an alternative lung function test	10

South Central - Hampshire B Research Ethics Committee Research Ethics Committee Annual Report

Further Information Unfavourable Opinion		
<b>REC Reference</b>	Title	Number of Days on Clock

Favourable Opinion with Standard Conditions		
<b>REC Reference</b>	Title	Number of Days on Clock
15/SC/0611	Enhancing Prognostication in Uveal Melanoma	10
16/SC/0126	Perineal trauma in women having vaginal delivery after previous OASIS	7

Favourable Opinion with Additional Conditions		
<b>REC Reference</b>	Title	Number of Days on Clock
15/SC/0612	Impact of Dental Sensitivity on Oral Health Related Quality of Life	10
16/SC/0060	EQUIP: Training to promote user involvement in care planning SP-audit	6
16/SC/0128	Hypoglycaemia in young people with type 1 diabetes v1	7
16/SC/0177	Assessment of the obese patient for total knee arthroplasty	13

Unfavourable Op	nion	
<b>REC Reference</b>	Title	Number of Days on Clock

<b>Provisional Opini</b>	on	
<b>REC Reference</b>	Title	Number of Days on Clock

Further information response not complete		
<b>REC Reference</b>	Title	Number of Days on Clock

Withdrawn after t	he meeting	
<b>REC Reference</b>	Title	Number of Days on Clock

#### Table 10.1: Breakdown of current status of all substantial amendments reviewed within the reporting period

Amendment REC	Title	Version	Date	Number of Days on
Reference			2410	Clock
08/H0501/17/AM09	New markers of allergic reactions and anaphylaxis	Amendment 8	10/03/2015	34
08/H0504/73/AM09	A3671024 A study for patients who have received CP-675,206 previously	SA4	08/04/2015	8
08/H0504/73/AM11	A3671024 A study for patients who have received CP-675,206 previously	Amendment 5	26/06/2015	17
09/H0504/125/AM05	Genetics of Paediatric Inflammatory Bowel Disease	SA4; 20/11/2015	20/11/2015	7
09/H0504/129/AM10	3rd Generation Isle of Wight Birth Cohort (Version 1)	SA6	12/03/2015	22
10/H0501/26/AM06	The PADPROM Project: quality of life of pad users questionnaire.	5	23/03/2015	14
10/H0501/39/AM05	Myeloid-derived suppressor cells in haematological malignancies	4	26/03/2015	19
10/H0504/73/AM01	Breast cancer biomarker translational research and validation study.	Substantial Amendment 1	10/07/2015	9
10/H0504/90/AM13	TREATMENT OF IRON DEFICIENCY ANAEMIA IN ADOLESCENTS WITH IBD.	Protocol Amendment 4; v7.2	21/07/2015	10
10/H0504/93/AM12	A Phase III Study of INC424 in Polycythemia Vera Patients	07/04/2015 DMC	07/04/2015	8
11/SC/0084/AM08	ProT4 (Prophylactic Transfer of CD4 Lymphocytes)	05, 08.09.2015	08/09/2015	28
11/SC/0412/AM09	Development of Symptom Based Questionnaires for patients with cancer	SA7	01/04/2015	22
11/SC/0529/AM01	Modelling Placental Nutrient Transport	Substantial Amendment 1	31/03/2015	19
12/SC/0107/AM04	EAST: Early treatment of AF for Stroke prevention Trial: 09- Dec-2011	Amendment 3 (substantial): 10t	10/07/2015	28
12/SC/0115/AM03	ICoS (Inflammation, Cogntion, and Stress) Version 1.0	Amendment 3.0	22/06/2015	31
12/SC/0176/AM05	Inflammation and disability progression in multiple sclerosis	Substantial Amendment 3	14/05/2015	34
12/SC/0391/AM11	COAST - Cisplatin Ototoxicity attenuated by Aspirin Trial	Substantial Amendment 8	15/05/2015	14
12/SC/0391/AM12	COAST - Cisplatin Ototoxicity attenuated by Aspirin Trial	AM12 Substantial Amendment: SA	18/09/2015	16
12/SC/0394/AM13	COMPLEMENT A + B:	Amendment 7 -	28/08/2015	23

		Signature page		
12/SC/0411/AM10	Physiotherapy Rehabilitation for Osteoporotic Vertebral fracture(PROVE	Sub Amend 9 23.04.15	23/04/2015	8
12/SC/0428/AM07	YoDA Young Onset Dementia Assessment Study	SA6	05/03/2015	14
12/SC/0487/AM01	NeuroNEC	Substantial Amendment 1	16/06/2015	23
12/SC/0492/AM08	OXWATCH- Women and Wellbeing Study	6	08/04/2015	7
12/SC/0526/AM02	Arden Tissue Bank	2	21/04/2015	9
12/SC/0580/AM02	Views & Experience of Magnetic Resonance imaging during pregnacy	3 29/09/2015	29/09/2015	24
12/SC/0580/AM04	Views & Experience of Magnetic Resonance imaging during pregnacy	4	15/12/2015	24
13/SC/0041/AM03	Consent and confidentiality in genetic medicine	SA1	30/03/2015	16
13/SC/0041/AM04	Consent and confidentiality in genetic medicine	2	18/06/2015	21
13/SC/0041/AM05	Consent and confidentiality in genetic medicine	AM05 Substantial Amendment: 3	09/12/2015	14
13/SC/0081/AM01	What is the expereince of Young People being Taught Mindfulness in DBT	1	28/01/2014	24
13/SC/0092/AM12	CBAF312A2304 siponimod in secondary progressive multiple sclerosis v1	Protocol Amend 02	19/03/2015	21
13/SC/0092/AM13	CBAF312A2304 siponimod in secondary progressive multiple sclerosis v1	Substantial Amendment; 27.04.2	27/04/2015	9
13/SC/0092/AM14	CBAF312A2304 siponimod in secondary progressive multiple sclerosis v1	AM 14 - Substantial Amendment	08/07/2015	22
13/SC/0092/AM15	CBAF312A2304 siponimod in secondary progressive multiple sclerosis v1	Protocol v03	27/11/2015	25
13/SC/0102/AM11	MK3475-010-00	SA9	12/06/2015	26
13/SC/0102/AM13	MK3475-010-00	Protocol amendment 010	06/07/2015	14
13/SC/0102/AM17	MK3475-010-00	IB Edition 10, PISCF v10, GP I	09/10/2015	17
13/SC/0102/AM18	MK3475-010-00	AM18 Substantial Amendment	20/01/2016	19
13/SC/0105/AM04	Southampton Women's Survey 10-12yr follow-up	Substantial	19/06/2015	27

		Amendment 2		
13/SC/0268/AM08	Ease of use of TIP compared to TIS and colistimethate in P. aeruginosa	AM08	21/09/2015	15
13/SC/0279/AM08	Phase 3 study of TAF-containing combination STR in HIV-1 subjects	Substantial Amendment 5	15/05/2015	25
13/SC/0287/AM01	Development of a HRQOL questionnaire module for anal cancer patients	SA1	05/02/2015	15
13/SC/0323/AM08	PCI-32765DBL3001	INT2	14/09/2015	7
13/SC/0384/AM05	Tremilimumab in pleural or peritoneal malignant mesothelioma	Substantial Amendment 4	29/07/2015	27
13/SC/0394/AM06	METRIC(MR Enterography or ulTRasound In Crohn's disease)	Amendment no. 4; 15th June 201	15/06/2015	20
13/SC/0409/AM03	SPRING Southampton Pregnancy Intervention for the Next Generation	Substantial Amendment 3	01/06/2015	39
13/SC/0435/AM02	ABICUS Trial: Version 2	2	29/07/2015	23
13/SC/0478/AM17	LGX818, MEK162 and LGX818 vs vemurafenib in melanoma patients.	Substantial Amendment 10	21/05/2015	7
13/SC/0478/AM18	LGX818, MEK162 and LGX818 vs vemurafenib in melanoma patients.	Substantial Amendment 11 – upd	15/09/2015	19
13/SC/0478/AM19	LGX818, MEK162 and LGX818 vs vemurafenib in melanoma patients.	AM19: Substantial Amendment: T	05/11/2015	14
13/SC/0495/AM02	Study to evaluate biology of keloids after different treatments v1.0	2	11/05/2015	21
13/SC/0559/AM05	Telotristat Etiprate for Carcinoid Syndrome Therapy – TELECAST	5	16/12/2015	27
13/SC/0592/AM01	Barts Pancreas Tissue Bank	1	01/04/2015	18
13/SC/0644/AM07	UNBLOCS: UriNary oBstruction relieved by Laser Or Conventional Surgery	Amendment 3	12/05/2015	13
13/SC/0645/AM02	PHOENIX Study - Version 1	SA2	10/03/2015	27
13/SC/0645/AM04	PHOENIX Study - Version 1	AM04 - SA3 - 03 7 October 2015	07/10/2015	8
14/SC/0039/AM04	PDSAFE trial	4	12/03/2015	16
14/SC/0039/AM05	PDSAFE trial	Amendment 5	02/07/2015	15
14/SC/0051/AM03	Frailty in older adults living with HIV - version 1.0	Substantial Amendment: Third	26/10/2015	15

		а		
14/SC/0066/AM01	EDICT - Exercise inDuced changes In Colorectal Cancer	AM01 Substantial	04/02/2016	21
	Tissues	Amendment		
14/SC/0098/AM01	UK Brain Archive Information Network (BRAIN UK)	Substantial	17/04/2015	14
		Amendment 1		
4/SC/0102/AM04	Neural responses to reward and aversion in depressed	Substantial	05/05/2015	21
	adolescents	Amendment 4		
4/SC/0160/AM03	iFAAM	Amendment 3	05/06/2015	17
4/SC/0160/AM04	iFAAM	Amendment 4	12/08/2015	25
4/SC/0221/AM03	CONCEPT	Amendment 3	01/06/2015	27
4/SC/0221/AM05	CONCEPT	AM05 Substantial	15/01/2016	24
		Amendment 4,		
14/SC/1034/AM02	Prostate Cancer UK Module 3 Phase 1: Evaluation of existing clamps	SA2	09/04/2015	20
14/SC/1034/AM03	Prostate Cancer UK Module 3 Phase 1: Evaluation of existing clamps	Amendment 3	08/07/2015	6
14/SC/1034/AM04	Prostate Cancer UK Module 3 Phase 1: Evaluation of existing clamps	AM04: Substantial Amendment 4	01/10/2015	17
14/SC/1034/AM05	Prostate Cancer UK Module 3 Phase 1: Evaluation of existing clamps	5	03/12/2015	15
14/SC/1034/AM06	Prostate Cancer UK Module 3 Phase 1: Evaluation of existing clamps	6	03/02/2016	28
14/SC/1126/AM03	GALA-BIDD	Amendment 3	27/01/2016	25
14/SC/1156/AM01	JAVA-P	SA1	20/02/2015	16
14/SC/1156/AM07	JAVA-P	AM07 Substantial Amendment 2 1	10/11/2015	18
14/SC/1167/AM02	A study of patritumab with erlotinib in subjects with NSCLC	Substantial Amendment 1	22/05/2015	32
14/SC/1167/AM04	A study of patritumab with erlotinib in subjects with NSCLC	AM04 - Updated IB, PIS and CF	24/11/2015	28
14/SC/1169/AM03	SPACE FOR COPD in primary care: a pragmatic trial	Amendment 4 (1st Substantial A	19/05/2015	15
14/SC/1169/AM06	SPACE FOR COPD in primary care: a pragmatic trial	AM06 (2nd substantial amendmen	25/06/2015	20
14/SC/1169/AM08	SPACE FOR COPD in primary care: a pragmatic trial	3	11/12/2015	28

14/SC/1177/AM03	Prostate Cancer UK Module 4 Phase 1: Evaluation of existing products	Substantial Amendment: 3 08/10	08/10/2015	28
14/SC/1200/AM01	Investigating immunogenicity to biopharmaceutics cross sectional study	AM01	11/11/2015	9
14/SC/1223/AM05	CALIBER	AM05: CALIBER - Substantial Am	26/01/2016	13
14/SC/1227/AM01	Patients' expectations and experience of caudal epidural injections	1	04/09/2015	8
14/SC/1236/AM02	GO28399 Open label extension study of Vemurafenib	SA2 Protocol GO28399, V4, IB12	11/06/2015	27
14/SC/1323/AM01	EDC Biomarker Discovery in Colorectal and Lung Cancer	Substantial Amendment 1	14/07/2015	8
14/SC/1334/AM01	PREHEAT Trial - local heat preconditioning and wound healing	SA1	26/03/2015	9
14/SC/1337/AM03	200977 Study of Albiglutide in patients with Type 2 Diabetes Mellitus	2	26/03/2015	14
14/SC/1337/AM05	200977 Study of Albiglutide in patients with Type 2 Diabetes Mellitus	Substantial Amendment 3	01/06/2015	20
14/SC/1337/AM08	200977 Study of Albiglutide in patients with Type 2 Diabetes Mellitus	AM08 Substantial Amendment: 4	24/09/2015	14
14/SC/1337/AM09	200977 Study of Albiglutide in patients with Type 2 Diabetes Mellitus	4.0	12/12/2015	26
14/SC/1340/AM09	LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD)	Global Protocol Amendment v03;	24/09/2015	17
14/SC/1340/AM11	LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD)	AM11	03/02/2016	20
14/SC/1340/AM12	LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD)	Protocol Amendment 4	16/02/2016	19
14/SC/1377/AM01	Evaluation of a milk ladder & immune markers in clinical practice	SA1	12/03/2015	20
14/SC/1377/AM02	Evaluation of a milk ladder & immune markers in clinical practice	Sub Amend 2 13/05/2015	13/05/2015	18
14/SC/1377/AM03	Evaluation of a milk ladder & immune markers in clinical practice	AM03 Substantial Amendment: No	13/11/2015	14
14/SC/1441/AM01	Development of new blood grouping reagents from excluded blood donors	Amendment number 1 08	11/11/2015	12

		October		
15/SC/0041/AM01	Nerve function and hyperthermia v1.4	1.7	24/11/2015	15
15/SC/0085/AM01	Role of vinegar in identifying abnormal cells in Barrett's	13/07/2015	13/07/2015	11
	oesophagus	Amendment No. 3		
15/SC/0104/AM01	Sarcopenia, nutritional intakes and outcomes in stem cell transplant	Amendment 1	07/08/2015	26
15/SC/0256/AM04	Inhaled Interferon Beta-1a vs placebo in asthma patients	AM04: Substantial	11/02/2016	21
		Amendment 3		
15/SC/0289/AM02	AMG 319 in HPV negative HNSCC	AM02 Substantial	12/02/2016	20
		Amendment: CT		
15/SC/0291/AM01	MO29518 - A phase II Study of MPDL3280A in Advanced Solid	Substantial	15/06/2015	21
	Tumours	Amendment 1		
15/SC/0291/AM05	MO29518 - A phase II Study of MPDL3280A in Advanced Solid	AM05 - Substantial	14/10/2015	20
	Tumours	Amendment		
15/SC/0315/AM01	BP29360 - RO5479599 in advanced or metastatic squamous	Substantial	19/06/2015	31
	NSCLC	Amendment 1		
15/SC/0442/AM01	The ANODE Trial	AM01 Substantial	03/12/2015	18
		Amendment: 1		
15/SC/0619/AM01	Liver function assessment by breath analysis	AM01 Substantial	19/02/2016	28
		Amendment 1 -		
15/SC/0640/AM01	CALYPSO	AM01 Substantial	18/02/2016	19
		Amendment 1,		
264/01/w/AM09	Radiolabelled Anti-CD66 monoclonal antibody (BW250/183)	AM09 Substantial	10/11/2015	26
		Amendment: 9		

Unfavourable opinio	n			
Amendment REC Reference	Title	Version	Date	Number of Days on Clock
10/H0504/25/AM06	Oxford Vaccine Centre Biobank	Substantial Amendment 2	10/06/2015	32
10/H0504/93/AM14	A Phase III Study of INC424 in Polycythemia Vera Patients	05	16/02/2016	27
12/SC/0428/AM09	YoDA Young Onset Dementia Assessment Study	AM09 Substantial Amendment 7 1	15/10/2015	26
14/SC/0160/AM05	iFAAM	AM05 Substantial Amendment 5,	06/11/2015	15
14/SC/1072/AM01	POMP v0.1	AM01 Substantial	26/01/2016	24

		Amendment1, 2		
14/SC/1340/AM01	LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD)	N/A	06/05/2015	21
14/SC/1340/AM07	LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD)	AM07 Substantial Amendment: GI	16/02/2015	15
15/SC/0045/AM01	THERAPIST Version 1.0	SA1	17/03/2015	20
15/SC/0496/AM01	Test-retest operator typical error for tHb-mass measurement.	1.2	28/08/2015	21
400/02/SW/AM01	Alcohol Consumpiton Studies in Hepatology Patients	Substantial Amendment 7, 08.06	08/06/2015	26

Table 10.2: Breakdown of current status of all modified amendments reviewed within the reporting period

Amendment REC Reference	Title	Version	Date	Number of Days on Clock
10/H0504/25/AM06/1	Oxford Vaccine Centre Biobank	Amendment 2 (modified)	10/06/2015	11
12/SC/0428/AM09/1	YoDA Young Onset Dementia Assessment Study	MA7	11/12/2015	3
12/SC/0580/AM01/1	Views & Experience of Magnetic Resonance imaging during pregnacy	SA2	27/04/2015	6
15/SC/0045/AM01/1	THERAPIST Version 1.0	Modified Amendment 1	07/05/2015	1

Unfavourable opinio	n timeline			
Amendment REC	Title	Version	Date	Number of Days on
Reference				Clock
14/SC/1340/AM01/1	LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial	Global Protocol	16/02/2015	10
	Of HD)	Amendment 02		

			exceeding timelines	s ex	able 11: Items o
		ne	for ethical review over 60 day timel	ns fo	II applications
Clock	Number of Days on Clock		Title	<b>)</b> .	C Reference
	Number of Days on C	 	litle	<b>;</b>	C Reference

Proportionate review applications for ethical review over 14 day timeline		
<b>REC Reference</b>	Title	Number of Days on Clock

SSAs (non Phase 1) over 25 day timeline		
<b>REC Reference</b>	Title	Number of Days on Clock

SSAs (Phase 1) over 14 day timeline		
<b>REC Reference</b>	Title	Number of Days on Clock

Substantial Amendments over 35 day timeline				
Amendment REC Reference	Title	Version	Date	Number of Days on Clock
13/SC/0409/AM03	SPRING Southampton Pregnancy Intervention for the Next Generation	Substantial Amendment 3	01/06/2015	39

Modified Amendments over 14 day timeline				
Amendment REC	Title	Version	Date	Number of Days on
Reference				Clock